Drug intelligence / Profile preview

ivosidenib

Development stage: Approved
Lead developer: Servier
Modality: Small Molecules
Administration: Oral

Overview

Ivosidenib is a small molecule inhibitor that selectively targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. By inhibiting mutant IDH1, it reduces the production of the oncometabolite D-2-hydroxyglutarate, which can promote tumorigenesis. Ivosidenib is primarily indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an IDH1 mutation and has also been approved for use in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation[6][7]. The drug was developed by Agios Pharmaceuticals and commercialized by Servier.

Brand names: Tibsovo拓舒沃
Other names: 艾伏尼布依维替尼

Targets

IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)

Beyond the preview

Go deeper on ivosidenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ivosidenib.

Explore the full profile